What is the current valuation of the Heart Transplantation Therapeutic Market as of 2024?

The Heart Transplantation Therapeutic Market was valued at 71.01 USD Billion in 2024. Read More

What is the projected market size for the Heart Transplantation Therapeutic Market by 2035?

The market is projected to reach 165.44 USD Billion by 2035. Read More

What is the expected CAGR for the Heart Transplantation Therapeutic Market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 7.99%. Read More

Which treatment type segment is projected to have the highest valuation by 2035?

The Heart Transplantation segment is projected to reach between 60.0 and 25.0 USD Billion by 2035. Read More

What are the projected valuations for the Left Ventricular Assist Device (LVAD) segment by 2035?

The LVAD segment is expected to reach between 45.0 and 20.0 USD Billion by 2035. Read More

How does the valuation of the Deceased Donor segment compare to the Living Donor segment by 2035?

By 2035, the Deceased Donor segment is projected to be valued between 105.0 and 45.0 USD Billion, significantly higher than the Living Donor segment, which is expected to reach between 60.44 and 26.01 USD Billion. Read More

What age group is expected to have the highest market valuation in the Heart Transplantation Therapeutic Market by 2035?

The 65 Years and Above age group is projected to reach between 83.44 and 36.01 USD Billion by 2035. Read More

Which indication segment is anticipated to show the highest growth by 2035?

The Ischemic Heart Disease indication segment is projected to reach between 65.0 and 28.0 USD Billion by 2035. Read More

Who are the key players in the Heart Transplantation Therapeutic Market?

Key players in the market include AbbVie, Bristol-Myers Squibb, Novartis, Roche, Pfizer, AstraZeneca, Merck & Co., Gilead Sciences, and Amgen. Read More

What trends are influencing the growth of the Heart Transplantation Therapeutic Market?

Trends such as advancements in treatment technologies and increasing prevalence of heart diseases are likely to influence market growth. Read More

Heart Transplantation Therapeutic Market

ID: MRFR/HC/28219-HCR

128 Pages

Rahul Gotadki

Last Updated: April 15, 2026

Heart Transplantation Therapeutic Market Research Report By Treatment Type (Heart Transplantation, Left Ventricular Assist Device (LVAD), Extracorporeal Membrane Oxygenation (ECMO), Implantable Cardiac Defibrillator (ICD)), By Donor Source (Deceased Donor, Living Donor), By Recipient Age (0-17 Years, 18-64 Years, 65 Years and Above), By Indication (Ischemic Heart Disease, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Valvular Heart Disease) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Treatment Type (USD Billion) | |
  1. 4.1.1 Heart Transplantation | |
  2. 4.1.2 Left Ventricular Assist Device (LVAD) | |
  3. 4.1.3 Extracorporeal Membrane Oxygenation (ECMO) | |
  4. 4.1.4 Implantable Cardiac Defibrillator (ICD) |
2. 4.2 Healthcare, BY Donor Source (USD Billion) | |
  1. 4.2.1 Deceased Donor | |
  2. 4.2.2 Living Donor |
3. 4.3 Healthcare, BY Recipient Age (USD Billion) | |
  1. 4.3.1 0-17 Years | |
  2. 4.3.2 18-64 Years | |
  3. 4.3.3 65 Years and Above |
4. 4.4 Healthcare, BY Indication (USD Billion) | |
  1. 4.4.1 Ischemic Heart Disease | |
  2. 4.4.2 Dilated Cardiomyopathy | |
  3. 4.4.3 Hypertrophic Cardiomyopathy | |
  4. 4.4.4 Valvular Heart Disease |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 AbbVie (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bristol-Myers Squibb (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Novartis (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Roche (CH) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Pfizer (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 AstraZeneca (GB) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Merck & Co. (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Gilead Sciences (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Amgen (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE |
7. 6.4 US MARKET ANALYSIS BY DONOR SOURCE |
8. 6.5 US MARKET ANALYSIS BY RECIPIENT AGE |
9. 6.6 US MARKET ANALYSIS BY INDICATION |
10. 6.7 CANADA MARKET ANALYSIS BY TREATMENT TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY DONOR SOURCE |
12. 6.9 CANADA MARKET ANALYSIS BY RECIPIENT AGE |
13. 6.10 CANADA MARKET ANALYSIS BY INDICATION |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY DONOR SOURCE |
17. 6.14 GERMANY MARKET ANALYSIS BY RECIPIENT AGE |
18. 6.15 GERMANY MARKET ANALYSIS BY INDICATION |
19. 6.16 UK MARKET ANALYSIS BY TREATMENT TYPE |
20. 6.17 UK MARKET ANALYSIS BY DONOR SOURCE |
21. 6.18 UK MARKET ANALYSIS BY RECIPIENT AGE |
22. 6.19 UK MARKET ANALYSIS BY INDICATION |
23. 6.20 FRANCE MARKET ANALYSIS BY TREATMENT TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY DONOR SOURCE |
25. 6.22 FRANCE MARKET ANALYSIS BY RECIPIENT AGE |
26. 6.23 FRANCE MARKET ANALYSIS BY INDICATION |
27. 6.24 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY DONOR SOURCE |
29. 6.26 RUSSIA MARKET ANALYSIS BY RECIPIENT AGE |
30. 6.27 RUSSIA MARKET ANALYSIS BY INDICATION |
31. 6.28 ITALY MARKET ANALYSIS BY TREATMENT TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY DONOR SOURCE |
33. 6.30 ITALY MARKET ANALYSIS BY RECIPIENT AGE |
34. 6.31 ITALY MARKET ANALYSIS BY INDICATION |
35. 6.32 SPAIN MARKET ANALYSIS BY TREATMENT TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY DONOR SOURCE |
37. 6.34 SPAIN MARKET ANALYSIS BY RECIPIENT AGE |
38. 6.35 SPAIN MARKET ANALYSIS BY INDICATION |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DONOR SOURCE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY RECIPIENT AGE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TREATMENT TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY DONOR SOURCE |
46. 6.43 CHINA MARKET ANALYSIS BY RECIPIENT AGE |
47. 6.44 CHINA MARKET ANALYSIS BY INDICATION |
48. 6.45 INDIA MARKET ANALYSIS BY TREATMENT TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY DONOR SOURCE |
50. 6.47 INDIA MARKET ANALYSIS BY RECIPIENT AGE |
51. 6.48 INDIA MARKET ANALYSIS BY INDICATION |
52. 6.49 JAPAN MARKET ANALYSIS BY TREATMENT TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY DONOR SOURCE |
54. 6.51 JAPAN MARKET ANALYSIS BY RECIPIENT AGE |
55. 6.52 JAPAN MARKET ANALYSIS BY INDICATION |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DONOR SOURCE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY RECIPIENT AGE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY DONOR SOURCE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY RECIPIENT AGE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY INDICATION |
64. 6.61 THAILAND MARKET ANALYSIS BY TREATMENT TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY DONOR SOURCE |
66. 6.63 THAILAND MARKET ANALYSIS BY RECIPIENT AGE |
67. 6.64 THAILAND MARKET ANALYSIS BY INDICATION |
68. 6.65 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY DONOR SOURCE |
70. 6.67 INDONESIA MARKET ANALYSIS BY RECIPIENT AGE |
71. 6.68 INDONESIA MARKET ANALYSIS BY INDICATION |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY DONOR SOURCE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY RECIPIENT AGE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY INDICATION |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY DONOR SOURCE |
79. 6.76 BRAZIL MARKET ANALYSIS BY RECIPIENT AGE |
80. 6.77 BRAZIL MARKET ANALYSIS BY INDICATION |
81. 6.78 MEXICO MARKET ANALYSIS BY TREATMENT TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY DONOR SOURCE |
83. 6.80 MEXICO MARKET ANALYSIS BY RECIPIENT AGE |
84. 6.81 MEXICO MARKET ANALYSIS BY INDICATION |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY DONOR SOURCE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY RECIPIENT AGE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY INDICATION |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DONOR SOURCE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY RECIPIENT AGE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DONOR SOURCE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY RECIPIENT AGE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DONOR SOURCE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY RECIPIENT AGE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY DONOR SOURCE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY RECIPIENT AGE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY INDICATION |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY DONOR SOURCE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY DONOR SOURCE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY RECIPIENT AGE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY RECIPIENT AGE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY INDICATION, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY INDICATION, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY INDICATION, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY INDICATION, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY INDICATION, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY INDICATION, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY INDICATION, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY INDICATION, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY INDICATION, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY INDICATION, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY INDICATION, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY INDICATION, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY INDICATION, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY INDICATION, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY INDICATION, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY INDICATION, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY INDICATION, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY INDICATION, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY INDICATION, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY INDICATION, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY INDICATION, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY INDICATION, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY INDICATION, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY INDICATION, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY INDICATION, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY INDICATION, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY INDICATION, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY INDICATION, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY INDICATION, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DONOR SOURCE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY RECIPIENT AGE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY INDICATION, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Heart Transplantation Therapeutic Market Segmentation

Heart Transplantation Therapeutic Market By Treatment Type (USD Billion, 2025-2035)

Heart Transplantation
Left Ventricular Assist Device (LVAD)
Extracorporeal Membrane Oxygenation (ECMO)
Implantable Cardiac Defibrillator (ICD)

Heart Transplantation Therapeutic Market By Donor Source (USD Billion, 2025-2035)

Deceased Donor
Living Donor

Heart Transplantation Therapeutic Market By Recipient Age (USD Billion, 2025-2035)

0-17 Years
18-64 Years
65 Years and Above

Heart Transplantation Therapeutic Market By Indication (USD Billion, 2025-2035)

Ischemic Heart Disease
Dilated Cardiomyopathy
Hypertrophic Cardiomyopathy
Valvular Heart Disease

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”